Effect of Sarcopenia and Frailty on Rocuronium Pharmacodynamics in Geriatric Patients

This prospective observational study aims to evaluate whether sarcopenia and frailty affect the pharmacodynamic profile of rocuronium in geriatric patients undergoing elective surgery under general anesthesia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenia Atrophy Frailty Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Blockade Neuromuscular Manifestations Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Pharmacodynamics Rocuronium Signs and Symptoms

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Betul Kozanhan

Konya, 42005, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Scheduled to undergo elective surgery under general anesthesia requiring endotracheal intubation
Planned use of rocuronium for neuromuscular blockade
Quantitative neuromuscular monitoring planned during anesthesia
American Society of Anesthesiologists physical status I-III
Ability to provide written informed consent
Completion of preoperative frailty and sarcopenia assessment

Exclusion criteria

Emergency surgery
Known neuromuscular disease
History of allergy or contraindication to rocuronium, sugammadex
Severe hepatic insufficiency
Severe renal insufficiency
Use of drugs known to significantly affect neuromuscular transmission
Preoperative mechanical ventilation or intensive care unit admission
Inability to perform a frailty or sarcopenia assessment
Patients in whom quantitative neuromuscular monitoring cannot be properly performed
Refusal to participate in the study

Treatment and study plan

Primary outcomes

Rocuronium onset time

Time frame: Perioperative/Periprocedural - during anesthesia induction

Time from intravenous administration of rocuronium to disappearance of all train-of-four responses, defined as train-of-four count 0, measured using quantitative neuromuscular monitoring

Secondary outcomes

Time from train-of-four count 0 to train-of-four count 2

Time frame: From achievement of train-of-four count 0 after the initial rocuronium dose until recovery of train-of-four count 2 during surgery

Time elapsed from achievement of train-of-four count 0 after the initial rocuronium dose to recovery of train-of-four count 2, recorded in minutes and measured using quantitative neuromuscular monitoring.
Time to train-of-four ratio 0.9 after sugammadex administration

Time frame: From sugammadex administration until recovery of train-of-four ratio to 0.9 at the end of surgery

Time from sugammadex administration to recovery of train-of-four ratio to 0.9, measured using quantitative neuromuscular monitoring.
Total rocuronium dose

Time frame: From anesthesia induction until the end of surgery

Total dose of rocuronium administered during anesthesia

Sponsors and collaborators

Lead sponsor

Konya Meram State Hospital

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: May 12, 2026
Registry last updated: Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed